To the full analysis
Arbutus Biopharma stock: growth
ABUSArbutus Biopharma reported $14.08M in revenue for fiscal 2025, up 128.2% on the prior year, up 15.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
0.2%
per year from 2006 to 2025, per share −18.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 15.3% | −5.5% | 0.2% |
| Revenue per share | −4.2% | −18.2% | −18.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $13.6M | $18.08M | −$2.72M |
| 2007 | $15.92M | −$2.58M | −$4.08M |
| 2008 | $9.64M | −$11.72M | −$9.45M |
| 2009 | $13.78M | −$9.33M | −$6.86M |
| 2010 | $21.35M | −$12.41M | −$12.08M |
| 2011 | $16.3M | −$9.73M | −$7.58M |
| 2012 | $14.18M | $29.95M | $33.26M |
| 2013 | $15.46M | −$14.06M | −$7.46M |
| 2014 | $15M | −$38.8M | −$13.48M |
| 2015 | $24.87M | −$61.12M | −$57.07M |
| 2016 | $1.5M | −$384.1M | −$61.88M |
| 2017 | $10.7M | −$84.4M | −$55.86M |
| 2018 | $5.9M | −$57.1M | −$69.04M |
| 2019 | $6.01M | −$153.72M | −$71.6M |
| 2020 | $6.91M | −$63.75M | −$51.67M |
| 2021 | $10.99M | −$76.25M | −$68.34M |
| 2022 | $39.02M | −$69.46M | −$35.87M |
| 2023 | $18.14M | −$72.85M | −$86.94M |
| 2024 | $6.17M | −$69.92M | −$65.03M |
| 2025 | $14.08M | −$33.5M | −$39.64M |
Revenue by segment
How Arbutus Biopharma Corp makes its money and how that has shifted. Names are as the company reports them.
- License$10.4M74%
- Non-Cash Royalty$1.5M11%
- Service, Other$800.0K6%
- Other$1.4M10%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| License | $10.43M | 74.1% |
| Non-Cash Royalty | $1.48M | 10.5% |
| Service, Other | $800K | 5.7% |
| Other | $1.37M | 9.7% |
| Total revenue | $14.08M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.